Microdosing Mounjaro for Maintenance: Is Staying on a Lower Dose the Right Call?

What "microdosing for maintenance" actually means, and why people try it

The phrase circulates on forums and social media, but it rarely means the same thing twice. Some people use it to describe staying at 2.5mg rather than titrating further. Others mean deliberately stepping back down from, say, 10mg to 5mg once their weight has stabilised. A smaller group describe taking their pen less frequently than once a week (every ten days or fortnightly) hoping to stretch supply or reduce side effects once they're no longer actively losing weight.

The appeal is understandable. These medicines aren't cheap, GI side effects tend to be most noticeable on the way up, and once the scale stops moving it feels logical to ask whether the full therapeutic dose is still necessary. The NHS's own guidance on weight-management injections acknowledges that long-term use is the expected picture for most people, but the optimal maintenance dose for an individual is a clinical judgement, not a formula.

The risk in self-directed dose reduction is real. Tirzepatide's appetite-suppressing effect is dose-dependent: a lower dose means a lower level of receptor activity, which for many people translates to a gradual creep in appetite and then weight. How quickly that happens, and at what dose it stops mattering, varies between individuals in ways that aren't predictable without monitoring.

What the clinical data tells us about staying on a lower dose of tirzepatide

The SURMOUNT-1 trial, published in the New England Journal of Medicine, studied tirzepatide at 5mg, 10mg and 15mg against placebo over 72 weeks in adults with obesity. Average weight reductions across the three active doses ranged from around 15% to around 21%, the higher doses producing the larger reductions. Critically, participants at 5mg still achieved meaningful, sustained weight loss compared with placebo. That tells us 5mg is not inert; it's a real therapeutic dose for some people, not just a stepping stone.

What the trial data doesn't include is a formal "step-down" arm where participants were titrated to their maximum dose and then reduced. That kind of long-term maintenance trial is underway in the research community, but the results aren't yet part of the evidence base that UK prescribers can apply directly. The existing guidance from NICE's appraisal of tirzepatide (TA1026) focuses on the highest tolerated dose for weight loss, with a review if less than 5% weight loss is achieved after six months, it doesn't map out what happens once a target weight is reached.

For a detailed look at how prescribers approach the specific question of Mounjaro maintenance dosing as a formal concept, that page covers the clinical reasoning in full.

The decision framework: three things that actually shape the dose conversation

When a patient raises maintenance dosing, a prescriber is weighing three things simultaneously.

First: how stable is your current weight, and for how long? A plateau of a few weeks during active treatment is different from six months of genuine stabilisation at a weight that also shows improved health markers. The latter gives a prescriber a firmer foundation for trialling a lower dose.

Second: what dose are you currently on, and what was your starting BMI? Someone who reached their target weight on 5mg and has been stable for several months is a different clinical picture from someone who needed 15mg throughout. The question of which dose counts as a "microdose" for maintenance purposes depends entirely on where you started.

Third: what happens if weight starts to return? The prescriber needs to know you're being monitored, that there's a plan to review and, if needed, step back up. This is why every repeat order at nume is clinically re-reviewed; weight is checked, not assumed. A reduction in dose without that safety net is where people run into difficulty.

If you're currently on treatment and wondering about the cost side of maintenance, the Mounjaro cost page sets out what private treatment involves transparently.

What microdosing tirzepatide does not mean, and the safety lines to hold

Extending the interval between doses (taking a weekly injection every ten days or fortnightly, rather than reducing to a lower weekly dose) is not a licensed approach. The medicine's pharmacokinetics are designed around a seven-day cycle; stretching that gap changes the plasma levels in ways that aren't studied for safety or effectiveness. It also risks the kind of missed-dose patterns that need careful handling. The guidance on what to do if you miss a Mounjaro dose is worth reading if this is something you're considering, the answer is more nuanced than most people expect.

Equally, the 2.5mg starting dose has a specific function: it's a tolerability period, designed to let your digestive system adjust before the dose that does therapeutic work. Settling permanently at 2.5mg is possible in principle, but for most people it won't maintain the weight loss achieved on a higher dose. If you want to understand what staying at the introductory dose actually involves, the page on microdosing Mounjaro at 2.5mg explains the reasoning and the limitations in detail. The detail on 2.5mg as a maintenance dose covers when it might, and might not, be appropriate.

If you'd like to explore your options with a prescriber who can review your individual situation, checking your eligibility is the right first step.